TD Cowen Raises its Price Target on Roivant Sciences (ROIV)
TD Cowen raised its price target on Roivant Sciences (ROIV) to $41 from $38 and kept a Buy rating, citing “impressive” Phase 2b D2T RA topline data for IMVT-1402 (ACR20 73%, ACR50 55%, ACR70 36%) and additional 2026 catalysts. Citi raised its target to $42 from $35, also Buy. Roivant reported Q4 EPS 28c vs -35c consensus and revenue $2.52M vs $3.91M.
How this was made
The 30-second read
Why it matters
Raised targets and reiterated Buy ratings are catalyst-anchored to IMVT-1402 efficacy signals (ACR20/50/70) and a pipeline timeline (expected brepocitinib launch in DM by end-September; upcoming data in NIU, CLE, PH-ILD, and D2T RA). However, the company’s reported fiscal Q4 EPS beat but revenue materially missed consensus, which may temper the magnitude of any rerating.
Market read
Sell-side target hikes tied to Phase 2b RA topline results and a dense 2H26 catalyst calendar are likely to support ROIV sentiment, even as the latest quarter’s revenue miss adds caution.
What to watch
Follow-up data quality (durability, safety/tolerability, and endpoint hierarchy) and timing risk around the multiple 2H26 updates could drive reversals despite raised price targets.
Background
The piece centers on sell-side target increases for Roivant Sciences following IMVT-1402 Phase 2b topline data in D2T RA, plus commentary on additional 2H26 catalysts and an FDA Breakthrough Therapy designation for brepocitinib in cutaneous sarcoidosis.
Ticker impact
TD Cowen and Citi raised ROIV price targets after IMVT-1402 Phase 2b D2T RA topline data and highlighted multiple 2H26 catalysts.
Likely modest positive bias for ROIV as sell-side revisions reinforce catalyst-driven upside into 2H26; near-term volatility possible given weak Q4 revenue vs consensus.
The article links the target increases directly to IMVT-1402 topline metrics and reiterates additional 2H26 updates (including brepocitinib launch expectations), while also noting Q4 revenue missed consensus, which can cap upside.
Market effects
Reinforces risk-on sentiment for small-cap biotech with immunology/RA assets when Phase 2b readouts look strong and multiple follow-on catalysts are scheduled.
Primarily US small/mid-cap biotech sentiment; limited direct regional spillover beyond biotech coverage.
Moderate: trial data and FDA Breakthrough Therapy designation can influence global biotech investor appetite for similar mechanisms.
Counterpoint
Topline Phase 2b metrics may not translate into durable endpoints or confirmatory trial success; revenue miss in the quarter suggests the market may still discount near-term commercialization.
Key entities
- companyRoivant Sciences Ltd.
Subject of the article; analysts raised price targets citing IMVT-1402 Phase 2b D2T RA topline data and upcoming 2H26 catalysts.
- analyst_firmTD Cowen
Raised its ROIV price target to $41 from $38 and maintained Buy after IMVT-1402 data.
- analyst_firmCiti
Raised its ROIV price target to $42 from $35 and maintained Buy, calling out further upside from 2H26 data catalysts.
- clinical_programIMVT-1402
Phase 2b D2T RA program referenced for topline efficacy metrics (ACR20/50/70).
- drug_programbrepocitinib
FDA Breakthrough Therapy designation mentioned for cutaneous sarcoidosis; expected DM launch by end-September and multiple upcoming data updates.
